{"id":134,"date":"2024-04-16T11:00:29","date_gmt":"2024-04-16T11:00:29","guid":{"rendered":"https:\/\/www.merckvaccines.com\/gardasil9\/?page_id=134"},"modified":"2025-12-15T11:31:53","modified_gmt":"2025-12-15T11:31:53","slug":"efficacy","status":"publish","type":"page","link":"https:\/\/www.merckvaccines.com\/gardasil9\/efficacy\/","title":{"rendered":"Efficacy"},"content":{"rendered":"\n\n
<\/div>\n\n\n\n\n

Efficacy against certain HPV-related cancers and diseases in individuals aged 16-26<\/span><\/strong><\/h1><\/div>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n

Efficacy of GARDASIL\u00ae<\/sup> [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] was assessed in 5 AAHS-controlled clinical studies<\/strong>.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n\n

~98%<\/strong> <\/h1>
\n

n=8493<\/p>\n\n\n\n

[95% CI, 93.5-99.8]<\/p>\n\n\n\n

Cervical Cancer<\/strong><\/p>\n\n\n\n

HPV 16- or 18-related CIN 2\/3 or AIS<\/p><\/div><\/div>\n\n\n\n

<\/p><\/div><\/div>\n\n\n\n

<\/div>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n\n\n
\n

100%<\/strong><\/h1>
\n

n=7772<\/p>\n\n\n\n

[95% CI, 55.5-100.0]<\/p>\n\n\n\n

Vulvar Cancer<\/strong><\/p><\/div><\/div>\n\n\n\n

HPV 16- or 18-related VIN 2\/3<\/p><\/div><\/div>\n\n\n\n

<\/p><\/div><\/div>\n\n\n\n

<\/p>\n\n\n\n

<\/p>\n\n\n\n

<\/div>\n<\/div><\/div><\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n

100%<\/strong><\/h1>
\n

n=7772<\/p>\n\n\n\n

[95% CI, 49.5-100.0]<\/p>\n\n\n\n

Vaginal Cancer<\/strong><\/strong><\/p><\/div><\/div>\n\n\n\n

HPV 16- or 18-related VaIN 2\/3<\/p><\/div><\/div>\n\n\n\n

<\/p><\/div><\/div>\n\n\n\n

<\/p>\n\n\n\n

<\/div>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n\n\n
\n

~75%<\/strong><\/h1>
\n

n=194<\/p>\n\n\n\n

[95% CI, 8.8-95.4]<\/p>\n\n\n\n

Anal Cancer<\/strong> in Males<\/strong><\/p><\/div><\/div>\n\n\n\n

HPV 6-, 11-, 16-, or 18-related AIN 2\/3<\/p><\/div><\/div>\n\n\n\n

<\/p><\/div><\/div>\n\n\n\n

<\/p>\n\n\n\n

<\/div>\n<\/div><\/div><\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

Efficacy and effectiveness of GARDASIL are relevant to GARDASIL 9 since the vaccines are manufactured similarly and contain 4 of the same HPV L1 VLPs.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n\n\n
Study design<\/span><\/a><\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

Efficacy of GARDASIL 9 against certain cancers caused by HPV Types 31, 33, 45, 52, and 58.<\/strong><\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

~97%<\/h1>
\n

n=6016<\/p>\n\n\n\n

[95% CI, 80.9-99.8]<\/p>\n\n\n\n

CIN 2\/3, AIS, Cervical<\/strong> Cancer<\/strong>, VIN 2\/3, VaIN 2\/3, Vulvar<\/strong> Cancer<\/strong>, and Vaginal Cancer<\/strong><\/strong><\/p><\/div><\/div>\n\n\n\n

HPV 31-, 33-, 45-, 52-, and 58-related<\/p><\/div><\/div>\n\n\n\n

(composite endpoint)<\/p><\/div><\/div>\n\n\n\n

<\/p><\/div><\/div>\n\n\n\n

<\/p>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n\n\n

<\/div>\n<\/div>\n\n\n\n
\n
Study design<\/span><\/a><\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

Efficacy against certain HPV-related cancers and diseases in individuals aged 27-45a<\/sup><\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n

Efficacy of GARDASIL\u00ae<\/sup> [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] in preventing HPV 6-, 11-, 16-, and 18-related endpoints in women in the PPE population:<\/strong><\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

~88%<\/h1>
\n

n=3253<\/p>\n\n\n\n

[95% CI: 75.4%, 94.6%]<\/p>\n\n\n\n

Genital Warts, VIN, VaIN, Vulvar<\/strong> Cancer, Vaginal Cancer, Cervical<\/strong> Dysplasia (Any Grade CIN), AIS, and Cervical Cancer<\/strong><\/p><\/div><\/div>\n\n\n\n

HPV 6-, 11-, 16-, and 18-related<\/p><\/div><\/div>\n\n\n\n

<\/p><\/div><\/div>\n\n\n\n

<\/div>\n<\/div><\/div><\/div><\/div>\n<\/div>\n\n\n\n
\n

95%<\/strong><\/h1>
\n

n=3253<\/p>\n\n\n\n

[95% CI: 68.7%, 99.9%]<\/p>\n\n\n\n

Genital Warts, Cervical Dysplasia<\/strong><\/p><\/div><\/div>\n\n\n\n

HPV 6-, 11-, 16-, and 18-related<\/p><\/div><\/div>\n\n\n\n

<\/p><\/div><\/div>\n\n\n\n

<\/p><\/div><\/div>\n\n\n\n

<\/div>\n<\/div><\/div><\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

a<\/sup>In men aged 27-45, effectiveness is inferred from efficacy data in women aged 27-45, and supported by immunogenicity data.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Effectiveness of GARDASIL 9 against HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in the PPI population<\/strong>.<\/p>\n\n\n\n

<\/div>\n\n\n\n

In women 27-45, effectiveness of GARDASIL 9 was supported by immunobridging comparisons to women 16-26, and supported by immunogenicity data.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Safety and effectiveness of GARDASIL 9 have not been established in pregnant women.<\/p>\n\n\n\n

Efficacy and effectiveness of GARDASIL are relevant to GARDASIL 9 since the vaccines are manufactured similarly and contain 4 of the same HPV L1 VLPs.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
Study design<\/span><\/a><\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

AAHS, amorphous aluminum hydroxyphosphate sulfate; AIN, anal intraepithelial neoplasia; AIS, adenocarcinoma in situ; CIN, cervical intraepithelial neoplasia; PPE, per-protocol efficacy; VaIN, vaginal intraepithelial neoplasia; VIN, vulvar intraepithelial neoplasia; VLP, virus-like particle.<\/p>\n\n\n\n

<\/div>\n\n\n\n
<\/div>\n\n\n\n\n
studyDesignEff1<\/span><\/div>
<\/i><\/a>

Study design & additional results<\/h3><\/div>
\n\n

GARDASIL\u00ae<\/sup><\/span> [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] study design<\/strong><\/p>\n\n\n

<\/div>\n\n\n

Efficacy of GARDASIL was assessed in 5 AAHS-controlled, double-blind, randomized clinical studies evaluating 24,596 individuals in the PPE population (20,541 girls and women 16 to 26 years of age and 4055 boys and men 16 to 26 years of age). Subjects received all 3 vaccinations within 1 year of enrollment, had no major deviations from the study protocol, were na\u00efve (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1, and remained PCR negative to the relevant HPV type(s) through 1 month post-dose 3 (Month 7).<\/p>\n\n\n

<\/div>\n\n\n

Additional GARDASIL<\/strong> study results<\/strong><\/p>\n\n\n

<\/div>\n\n\n

Cervical: 2 HPV 16- or 18-related CIN 2\/3 or AIS cases in the group receiving GARDASIL (n=8493) vs 112 cases in the group receiving placebo (n=8464) [95% CI, 93.5-99.8];<\/p>\n\n\n

<\/div>\n\n\n

Vulvar\/Vaginal: No HPV 16- or 18-related VIN 2\/3 or VaIN 2\/3 cases in either group receiving GARDASIL (n=7772) vs 10 cases in the VIN 2\/3 group receiving placebo (n=7744) [95% CI, 55.5-100.0], and 9 cases in the VaIN 2\/3 group receiving placebo (n=7744) [95% CI, 49.5-100.0];<\/p>\n\n\n

<\/div>\n\n\n

Anal: 3 (HPV Types 6-, 11-, 16-, or 18-related) AIN 2\/3 cases in the male group receiving GARDASIL (n=194) vs 13 cases in the male group receiving placebo (n=208) [95% CI, 8.8-95.4];<\/p>\n\n\n

<\/div>\n\n\n

Genital Warts: 3 HPV 6-, 11-, 16-, or 18-related genital warts cases in the male group receiving GARDASIL\u00ae<\/sup> [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] (n=1394) vs 28 genital warts cases in the male group receiving placebo (n=1404) [95% CI, 65.3-97.9]; External Genital Lesions (males): 3 cases HPV Types 6-, 11-, 16-, or 18-related external genital lesions in the group receiving GARDASIL (n=1394) vs 32 cases of external genital lesions in the group receiving placebo (n=1404) [95% CI, 70.1-98.2]; External Genital Lesions (females): 2 HPV 6-, 11-, 16-, or 18-related genital warts cases in the group receiving GARDASIL (n=7900) vs 193 cases in the group receiving placebo (n=7902) [95% CI, 96.2-99.9].<\/p>\n\n\n

<\/div>\n\n\n

GARDASIL\u00ae<\/sup>9  [Human Papillomavirus 9-valent Vaccine, Recombinant] study design<\/strong><\/p>\n\n\n

<\/div>\n\n\n

Efficacy of GARDASIL 9 in 16\u2010 through 26\u2010year\u2010old girls and women was assessed in an active comparator-controlled, double\u2010blind, randomized clinical study that included a total of 14, 204 women (GARDASIL 9=7099; GARDASIL\u00ae<\/sup> [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]=7105) who were enrolled and vaccinated without prescreening for the presence of HPV infection. Subjects were followed up with a median duration of 40 months (range 0 to 64 months) after the last vaccination and efficacy of all endpoints was measured starting after the Month 7 visit. Efficacy was evaluated in subjects who received all 3 vaccinations within 1 year of enrollment, had no major deviations from the study protocol, were na\u00efve to the relevant HPV type(s) (Types 31, 33, 45, 52, and 58) prior to dose 1, and remained PCR negative to the relevant HPV type(s) through 1 month post\u2010dose 3 (Month 7).<\/p>\n\n\n

<\/div>\n\n\n

GARDASIL 9 study results<\/strong><\/p>\n\n\n

<\/div>\n\n\n

One HPV 31-, 33-, 45-, 52-, and 58-related case (CIN 2\/3, AIS, cervical cancer, VIN 2\/3, VaIN 2\/3, vulvar cancer, and vaginal cancer) in the group receiving GARDASIL 9 (n=6016) vs 30 cases in the group receiving GARDASIL (n=6017) [95% CI, 80.9\u201099.8].<\/p>\n\n\n

<\/div>\n\n\n

AAHS, amorphous aluminum hydroxyphosphate sulfate; AIN, anal intraepithelial neoplasia; AIS, adenocarcinoma in situ; CI, confidence interval; CIN, cervical intraepithelial neoplasia; PCR, polymerase chain reaction; PPE, per-protocol efficacy; VaIN, vaginal intraepithelial neoplasia; VIN, vulvar intraepithelial neoplasia.<\/p><\/div><\/div>\n\n<\/div>

Button 1<\/a><\/div>
Button 2<\/a><\/div><\/div><\/div><\/div>
Button 1<\/a><\/div>
Button 2<\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n\n\n
studyDesignEff2<\/span><\/div>
<\/i><\/a>

Study design & additional results<\/h3><\/div>
\n\n

GARDASIL\u00ae<\/sup> [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] study design<\/strong><\/p>\n\n\n

<\/div>\n\n\n

A clinical trial evaluated efficacy of GARDASIL in 3253 women 27 through 45 years of age, based on a combined endpoint of HPV 6-, 11-, 16-, or 18-related persistent infection, genital warts, vulvar and vaginal dysplastic lesions of any grade, CIN of any grade, AIS, and cervical cancer. These women were randomized 1:1 to receive either GARDASIL or AAHS control. The PPE population received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, were na\u00efve (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and remained PCR negative to the relevant HPV type(s) through 1 month post-dose 3 (Month 7). The clinical trial was conducted in 2 phases: a base study and a long-term study extension.<\/p>\n\n\n

<\/div>\n\n\n

Additional study results<\/strong><\/p>\n\n\n

<\/div>\n\n\n

In the base study (median duration of follow-up of 3.5 years post-dose 3), the efficacy of GARDASIL against the combined incidence of HPV 6-, 11-, 16-, and 18-related persistent  infection, genital warts, VIN, VaIN, vulvar cancer, vaginal cancer, cervical dysplasia (any grade CIN), AIS, and cervical cancer in the PPE population was 87.7% (95% CI, 75.4%, 94.6%). The efficacy estimate for the combined endpoint was driven primarily by prevention of persistent infection. The efficacy of GARDASIL against the combined incidence of HPV 6-, 11-, 16-, and 18-related genital warts or cervical dysplasia was 95.0% (95% CI, 68.7%, 99.9%) in the PPE population. While no statistically significant efficacy was demonstrated for GARDASIL in the base study for prevention of cervical intraepithelial neoplasia grades 2 and 3 (CIN 2\/3), adenocarcinoma in situ (AIS), or cervical cancer related to HPV Types 16 and 18, there was 1 case of CIN 2\/3 observed in the GARDASIL group and 5 cases in the placebo group. The CIN 2 case in the GARDASIL group tested positive by PCR for HPV 16 and HPV 51.<\/p><\/div><\/div>\n\n<\/div>

Button 1<\/a><\/div>
Button 2<\/a><\/div><\/div><\/div><\/div>
Button 1<\/a><\/div>
Button 2<\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n\n\n
ExternalSitePopup<\/span><\/div>
<\/i><\/a>

By clicking on this link, you will be leaving Merck Vaccines.<\/h2><\/div>
<\/div>
Cancel<\/a><\/div>
Proceed<\/a><\/div><\/div><\/div><\/div>
Cancel<\/a><\/div>
Proceed<\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"

Efficacy of GARDASIL\u00ae [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] was assessed in 5 AAHS-controlled clinical studies. Efficacy…<\/p>\n","protected":false},"author":708,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_trash_the_other_posts":false,"editor_notices":[],"footnotes":""},"ga4_page_audience":[214],"ga4_page_birn_id":[],"ga4_page_branding":[231],"ga4_page_businessunit":[239],"ga4_page_campaign":[],"ga4_page_content_purpose":[259],"ga4_page_customer_journey_stage":[307],"ga4_page_customer_specialty":[353],"ga4_page_experience":[],"ga4_page_indication":[436],"ga4_page_material_intent":[512],"ga4_page_product":[548],"ga4_page_region":[739],"ga4_page_therapeuticarea":[784],"class_list":["post-134","page","type-page","status-publish"],"yoast_head":"\nEfficacy of GARDASIL\u00ae9 (Human Papillomavirus 9-valent Vaccine, Recombinant)<\/title>\n<meta name=\"description\" content=\"View efficacy data for GARDASIL\u00ae9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and review the study design and additional GARDASIL\u00ae [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] study results.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckvaccines.com\/gardasil9\/efficacy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Efficacy of GARDASIL\u00ae9 (Human Papillomavirus 9-valent Vaccine, Recombinant)\" \/>\n<meta property=\"og:description\" content=\"View efficacy data for GARDASIL\u00ae9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and review the study design and additional GARDASIL\u00ae [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] study results.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckvaccines.com\/gardasil9\/efficacy\/\" \/>\n<meta property=\"og:site_name\" content=\"gardasil9-mv\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-15T11:31:53+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Efficacy of GARDASIL\u00ae9 (Human Papillomavirus 9-valent Vaccine, Recombinant)","description":"View efficacy data for GARDASIL\u00ae9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and review the study design and additional GARDASIL\u00ae [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] study results.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckvaccines.com\/gardasil9\/efficacy\/","og_locale":"en_US","og_type":"article","og_title":"Efficacy of GARDASIL\u00ae9 (Human Papillomavirus 9-valent Vaccine, Recombinant)","og_description":"View efficacy data for GARDASIL\u00ae9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and review the study design and additional GARDASIL\u00ae [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] study results.","og_url":"https:\/\/www.merckvaccines.com\/gardasil9\/efficacy\/","og_site_name":"gardasil9-mv","article_modified_time":"2025-12-15T11:31:53+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckvaccines.com\/gardasil9\/efficacy\/","url":"https:\/\/www.merckvaccines.com\/gardasil9\/efficacy\/","name":"Efficacy of GARDASIL\u00ae9 (Human Papillomavirus 9-valent Vaccine, Recombinant)","isPartOf":{"@id":"https:\/\/www.merckvaccines.com\/gardasil9\/#website"},"datePublished":"2024-04-16T11:00:29+00:00","dateModified":"2025-12-15T11:31:53+00:00","description":"View efficacy data for GARDASIL\u00ae9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and review the study design and additional GARDASIL\u00ae [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] study results.","breadcrumb":{"@id":"https:\/\/www.merckvaccines.com\/gardasil9\/efficacy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckvaccines.com\/gardasil9\/efficacy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckvaccines.com\/gardasil9\/efficacy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckvaccines.com\/gardasil9\/"},{"@type":"ListItem","position":2,"name":"Efficacy"}]},{"@type":"WebSite","@id":"https:\/\/www.merckvaccines.com\/gardasil9\/#website","url":"https:\/\/www.merckvaccines.com\/gardasil9\/","name":"gardasil9-mv","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckvaccines.com\/gardasil9\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/pages\/134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/users\/708"}],"replies":[{"embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/comments?post=134"}],"version-history":[{"count":207,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/pages\/134\/revisions"}],"predecessor-version":[{"id":2798,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/pages\/134\/revisions\/2798"}],"wp:attachment":[{"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/media?parent=134"}],"wp:term":[{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/ga4_page_audience?post=134"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/ga4_page_birn_id?post=134"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/ga4_page_branding?post=134"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/ga4_page_businessunit?post=134"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/ga4_page_campaign?post=134"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=134"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=134"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=134"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/ga4_page_experience?post=134"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/ga4_page_indication?post=134"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/ga4_page_material_intent?post=134"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/ga4_page_product?post=134"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/ga4_page_region?post=134"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/gardasil9\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}